

## Genome-Wide Association Studies Suggest Limited Immune Gene Enrichment in Schizophrenia Compared to 5 Autoimmune Diseases

Jennie G. Pouget<sup>\*1-3</sup>, Vanessa F. Gonçalves<sup>1,3</sup>, Schizophrenia Working Group of the Psychiatric Genomics Consortium<sup>15</sup>, Sarah L. Spain<sup>4,5</sup>, Hilary K. Finucane<sup>6,7</sup>, Soumya Raychaudhuri<sup>8-12</sup>, James L. Kennedy<sup>1-3</sup>, and Jo Knight<sup>1-3,13,14</sup>

<sup>1</sup>Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada; <sup>2</sup>Institute of Medical Science, University of Toronto, Toronto, ON, Canada; <sup>3</sup>Department of Psychiatry, University of Toronto, Toronto, ON, Canada; <sup>4</sup>Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK; <sup>5</sup>Division of Genetics and Molecular Medicine, King's College London, London, UK; <sup>6</sup>Department of Mathematics, Massachusetts Institute of Technology, Cambridge, MA; <sup>7</sup>Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA; <sup>8</sup>Division of Genetics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; <sup>9</sup>Division of Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; <sup>10</sup>Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA; <sup>11</sup>Partners HealthCare Center for Personalized Genetic Medicine, Boston, MA; <sup>12</sup>Faculty of Medical and Human Sciences, University of Manchester, Manchester, UK; <sup>13</sup>Biostatistics Division, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada; <sup>14</sup>Lancaster Medical School and Data Science Institute, Lancaster University, Lancaster, UK; <sup>15</sup>A full list of members and affiliations appears in the [supplementary data](#).

\*To whom correspondence should be addressed; Centre for Addiction and Mental Health, 250 College Street, Toronto, Ontario M5T 1R8, Canada; tel: 416-535-8501, fax: 416-979-4666, e-mail: [jennie.pouget@mail.utoronto.ca](mailto:jennie.pouget@mail.utoronto.ca)

There has been intense debate over the immunological basis of schizophrenia, and the potential utility of adjunct immunotherapies. The major histocompatibility complex is consistently the most powerful region of association in genome-wide association studies (GWASs) of schizophrenia and has been interpreted as strong genetic evidence supporting the immune hypothesis. However, global pathway analyses provide inconsistent evidence of immune involvement in schizophrenia, and it remains unclear whether genetic data support an immune etiology per se. Here we empirically test the hypothesis that variation in immune genes contributes to schizophrenia. We show that there is no enrichment of immune loci outside of the MHC region in the largest genetic study of schizophrenia conducted to date, in contrast to 5 diseases of known immune origin. Among 108 regions of the genome previously associated with schizophrenia, we identify 6 immune candidates (*DPP4*, *HSPD1*, *EGRI*, *CLU*, *ESAM*, *NFATC3*) encoding proteins with alternative, nonimmune roles in the brain. While our findings do not refute evidence that has accumulated in support of the immune hypothesis, they suggest that genetically mediated alterations in immune function may not play a major role in schizophrenia susceptibility. Instead, there may be a role for pleiotropic effects of a small number of immune genes that also regulate brain development and plasticity. Whether immune alterations drive schizophrenia progression is an important question to be addressed by future research,

especially in light of the growing interest in applying immunotherapies in schizophrenia.

*Key words:* schizophrenia/genetic/immune/inflammation/autoimmune/inflammatory

### Introduction

Schizophrenia is a severe psychiatric disease that disturbs multiple aspects of mental function. Although its etiology remains poorly understood, liability is largely genetically mediated.<sup>1</sup> In the largest genome-wide association study (GWAS) yet conducted ( $n = 35\,476$  cases, 46\,839 controls), over 100 independent loci were robustly associated with the disease.<sup>2</sup> This GWAS represents a significant advance towards defining the molecular parts list for schizophrenia, and provides an opportunity to integrate genetic information with existing biological data to test specific etiological hypotheses.

Among many hypotheses of schizophrenia etiology, the longstanding immune theory posits that dysregulation of the immune system causes schizophrenia in at least a subset of patients.<sup>3-6</sup> It is known that immune components such as MHC class I,<sup>7</sup> TNF- $\alpha$ ,<sup>8</sup> complement,<sup>9</sup> TGF- $\beta$ ,<sup>10</sup> and IL-6<sup>11</sup> regulate brain development and adult neural plasticity. Exposure to the wrong level of an immune factor at the wrong time may consequently disrupt brain

development and adult neural functioning, as supported by *in utero* immune activation in rodents<sup>12</sup> and primates.<sup>13</sup> Many schizophrenia patients show hallmarks of immune disease—such as prior infection,<sup>14</sup> presence of autoantibodies,<sup>15</sup> co-occurring autoimmunity,<sup>16</sup> and inflammation,<sup>17,18</sup>—supporting the idea that immune disturbances may play a role in schizophrenia by disrupting brain development and/or adult neural function.

Given the immune disturbances apparent among schizophrenia patients, there is considerable interest in treating the disease with immune-modulating drugs.<sup>19</sup> Non-specific anti-inflammatory agents (eg, aspirin) have shown modest efficacy among schizophrenia patients,<sup>20</sup> and randomized controlled trials with more targeted immunotherapies (eg, Tocilizumab, a monoclonal antibody against the IL-6 receptor)<sup>21</sup> are currently underway. Importantly, the underlying cause of immune perturbation in schizophrenia remains unknown. A combination of genetic and environmental risk factors has been proposed to initiate immune abnormalities among patients with schizophrenia.<sup>22</sup> Alternatively, the immune disturbances may be epiphenomena driven by disease pathogenesis, exposure to antipsychotic drugs, or lifestyle factors associated with schizophrenia such as smoking. Immune profiling studies of schizophrenia have primarily been cross-sectional in nature, precluding causal inferences. Furthermore, important factors influencing immune status—such as hospitalization, age, sex, body mass index, diet, smoking, and medication use<sup>23</sup>—are associated with schizophrenia case status<sup>23</sup> and are not always accounted for. Thus, it remains unclear from the existing literature whether the relationship between schizophrenia and immune disturbances is causal, correlative, or an epiphenomenon. Adjunct immunotherapy may be a viable therapeutic option regardless of the role of immune dysregulation—whether it causes schizophrenia, influences disease progression, or is a biomarker for disease. However, clarifying the role of immune processes in schizophrenia has important implications for understanding disease biology, optimizing the timing of immunotherapy interventions, and developing effective targeted therapies.

If genetic variants influencing immune function were associated with elevated risk of schizophrenia, this would provide strong evidence that immune abnormalities are causal drivers of disease. Although genetic data have been interpreted as supporting immune involvement,<sup>22,24,25</sup> largely due to the strong association of single-nucleotide polymorphism (SNP) alleles in the extended major histocompatibility complex (xMHC),<sup>24</sup> previous studies have reported conflicting results with respect to immune pathway involvement. For instance, in gene set enrichment analysis of the Genetic Association Information Network (GAIN) schizophrenia GWAS (1158 cases and 1378 controls), 3 of the 7 overrepresented pathways were related to the immune system (TGF- $\beta$ , TNFR1, and TOB1 pathways).<sup>26</sup> In contrast, a more recent study integrating results across 5 different pathway analysis methods

observed enrichment of TGF- $\beta$  signaling after pooling GWAS results for major depressive disorder (9227 cases and 7383 controls), bipolar disorder (6990 cases and 4820 controls), and schizophrenia (9379 cases and 7736 controls) but no enrichment of immune pathways in schizophrenia alone.<sup>27</sup> Thus, it remains unclear whether the immune disturbances apparent in schizophrenia are genetically mediated.

Here we directly tested the hypothesis that common variation within immune genes contributes to schizophrenia in a total sample of 35476 schizophrenia cases and 46839 controls. We first evaluated the collective association and overall enrichment of SNPs within immune loci in schizophrenia to discern whether existing genetic data support an immunological cause of the disease. We then evaluated association of individual immune components with schizophrenia to identify candidates driving the immune disturbances observed in the disease.

## Subjects and Methods

### *Samples and Quality Control*

An overview of GWAS datasets analyzed, including information about immune SNP coverage, is provided in [table 1](#) and [supplementary table 1](#). All analyses used imputed genotype dosages or summary statistics generated according to quality control and imputation protocols described in the original GWASs.

### *Schizophrenia*

We analyzed data from the most recent schizophrenia GWAS conducted by the PGC.<sup>2</sup> The full dataset comprised 52 cohorts totaling 35476 cases and 46839 controls, and was described in detail in the primary GWAS analysis.<sup>2</sup> For analyses using individual-level SNP data, we analyzed the 36 European ancestry case-control cohorts for which we had ethics approval (25629 cases and 30976 controls, see [supplementary table 2](#) for details). For analyses using summary statistics we used summary results generated as described in the primary analysis.<sup>2</sup>

### *Autoimmune Diseases*

To evaluate the robustness of our approach to evaluate immune enrichment, and to benchmark our findings for

**Table 1.** Description of Samples

| Sample               | PMID     | Cases | Controls | Cohorts |
|----------------------|----------|-------|----------|---------|
| Schizophrenia        | 25056061 | 35476 | 46839    | 52      |
| Crohn's disease      | 21102463 | 6333  | 15056    | 6       |
| Multiple sclerosis   | 21833088 | 9772  | 17376    | 23      |
| Psoriasis            | 20953190 | 2178  | 5175     | 1       |
| Rheumatoid arthritis | 20453842 | 5539  | 20169    | 6       |
| Ulcerative colitis   | 21297633 | 6687  | 19718    | 6       |

schizophrenia, we analyzed GWAS summary statistics from 5 diseases of known immune origin: Crohn's disease (6333 cases and 15056 controls),<sup>28</sup> multiple sclerosis (9772 cases and 17376 controls),<sup>29</sup> psoriasis (2178 cases and 5175 controls),<sup>30</sup> rheumatoid arthritis (5539 cases and 20169 controls),<sup>31</sup> and ulcerative colitis (6687 cases and 19718 controls).<sup>32</sup> Multiple sclerosis, psoriasis, and rheumatoid arthritis have long been considered classic autoimmune diseases based on the presence of self-reactive immune cells, directed against a tissue-specific antigen. Crohn's disease and ulcerative colitis have historically been considered inflammatory diseases, but recent genetic data also support an autoimmune component.<sup>33</sup> For brevity, we refer to these 5 immune diseases of inflammatory and autoimmune origin as *autoimmune* throughout the article.

Access to the multiple sclerosis dataset<sup>29</sup> was obtained with permission from the International Multiple Sclerosis Genetics Consortium (IMSGC). Access to the psoriasis GWAS dataset<sup>30</sup> was obtained with permission from the Wellcome Trust Case Control Consortium (WTCCC), and imputed as described in Tsoi et al.<sup>34</sup> The remaining autoimmune disease GWAS datasets were publicly available (see [supplementary table 1](#) and Web Resources for details).

### Gene Sets

**Immune Gene Set.** We defined immune genes as those with an immune response annotation in Kyoto Encyclopedia of Genes and Genomes (KEGG), Gene Ontology (GO), Ingenuity, and Immunology Database and Analysis Portal (ImmPort) as accessed on Sept 21, 2014 (for details, see [supplementary table 3](#)). We included autosomal genes present in 3 of the 4 databases in our immune gene set. We excluded immune genes encoded in the xMHC (chromosome 6, 25–34 Mb), due to the broad association and extensive linkage disequilibrium (LD) in this region. All SNPs within the xMHC were also excluded from subsequent analyses.

Immune SNPs were defined as those falling within 50 kb upstream or downstream<sup>2</sup> of the transcribed region of genes in the immune gene list (973 genes representing 145 Mb, see [supplementary tables 1](#) and [4](#) for details of immune genes and SNP coverage).

**Null Gene Set.** To create the null gene set, we randomly selected 973 autosomal genes outside of the xMHC (representing 150 Mb), resulting in a list containing the same number of genes as the immune gene set. Null SNPs were defined using a 50 kb gene window.

**Brain Gene Set.** We used the brain gene set identified and previously described by Raychaudhuri et al,<sup>35</sup> with exclusion of those brain genes encoded within the xMHC. Briefly, brain genes were identified using 4 independent approaches: preferential gene expression in the brain compared to other tissues, neural-activity annotation by Panther, learning

annotation in Ingenuity, and synapse annotation in Gene Ontology. Brain SNPs were defined using a 50 kb gene window (2635 genes representing 589 Mb).

### Statistical Methods

**Association of Immune Genes in Schizophrenia.** To formally evaluate statistical significance of the immune hypothesis of schizophrenia, we performed a joint association analysis of all immune SNPs. This analysis included the 36 European ancestry case–control cohorts for which we had ethics approval (25629 cases and 30976 controls). Schizophrenia case status was permuted 100 times, an approach that created a null dataset while preserving the LD pattern between the 346253 immune SNPs available for analysis. For each permutation, association testing for each immune SNP was performed by logistic regression separately in each cohort adjusting for ten multidimensional scaling components (C1, C2, C3, C4, C5, C6, C7, C9, C15, C18), followed by inverse-variance weighted fixed effects meta-analysis. A sum of the Wald  $\chi^2$  (1 degree of freedom) test statistics for immune SNPs was obtained, and the empirical *P*-value was calculated as the proportion of permutation samples whose sum statistic was larger than that in the observed sample. The same permutation analysis was repeated for the null set of 290239 SNPs within 973 randomly selected genes as a baseline comparison.

**Benchmarking Immune Involvement Using Stratified LD Score Regression.** To benchmark genetically mediated immune involvement in schizophrenia, we applied stratified LD Score regression, which partitions heritability into functional categories while adjusting for LD-induced correlations and accepts summary statistics as input.<sup>36</sup> This method leverages the relationship between LD and association test statistics to estimate the per-SNP heritability attributable to a functional category by multiple regression of the association test statistic ( $\chi^2$ ) for SNP *j* against the LD Score of SNP *j* with respect to each functional category. Briefly, the regression coefficients obtained by multiple regression correspond to category-specific per-SNP heritabilities ( $\tau_j$ ) that account for the effects of all other categories, and can be used to estimate category-specific enrichment of SNP-based heritability ( $h^2_{\text{SNP}}$ ). Thus, stratified LD Score regression identifies a functional category as enriched for heritability if SNPs with high LD to that category have higher association test statistics than SNPs with low LD to that category. The enrichment estimates are defined as the proportion of SNP heritability explained by a functional category, normalized to the proportion of SNPs in that functional category. The statistical framework has been described in detail previously.<sup>36</sup>

To apply stratified LD Score regression we obtained summary statistics for 43 European-ancestry cohorts comprising the schizophrenia GWAS.<sup>36</sup> We considered only the subset of SNPs with available summary statistics that



overlapped HapMap Project Phase 3 (HapMap3)<sup>37</sup> SNPs (as a proxy for well-imputed SNPs), because stratified LD Score regression does not account for imperfect imputation. First, we calculated LD Scores for these HapMap3 SNPs with respect to the immune and brain SNP categories, as well as a baseline gene category that included all SNPs within a 50 kb window of the transcribed region of any gene. Next, we estimated enrichment of heritability for the immune and brain functional categories using a multiple linear regression model that included either the immune or brain annotations in addition to 54 overlapping categories (our baseline gene category, and the 53 annotations previously described by Finucane<sup>36</sup>), because the accuracy of enrichment estimates is improved by including many functional categories in the model. Standard error estimates were obtained by block jackknifing over 200 equally sized blocks of SNPs.<sup>36</sup>

*Immune Candidate Gene Identification.* To evaluate association of specific immune components with schizophrenia, we used summary statistics from the complete PGC schizophrenia GWAS.<sup>2</sup> Index SNPs, defined as the SNP with the smallest association *P*-value for each disease-associated locus and identified in the primary analysis of the PGC dataset as previously described.<sup>2</sup>

## Results

### *Immune Gene Set and Corresponding Immune SNPs*

To define an inclusive immune gene set we used an annotation-based approach which captured 973 autosomal immune genes, represented by a total of 587933 SNPs in the schizophrenia GWAS (see [supplementary table 4](#) for details of SNP coverage for immune genes). Although there is a robust xMHC association in schizophrenia, there is extensive LD in this region which can bias standard enrichment approaches and lead to false-positive results.<sup>38</sup> To avoid this bias, we excluded the xMHC from the main analyses, and focused on immune genes outside of this region. To substantiate that our approach did not exclude from investigation immune loci with a major role in schizophrenia, we fine-mapped the xMHC association in schizophrenia ([supplementary methods](#)). Concordant with previous reports,<sup>39,40</sup> the primary signals in schizophrenia captured by GWAS variants did not map to coding variants in the human leukocyte antigen (HLA) genes typically implicated in autoimmune disease. Instead, we found 3 independent xMHC associations in schizophrenia corresponding to SNPs that represented (1) an extended class I region association spanning ~2 Mb, (2) a class II region variant located near the C4 gene, concordant with the recent finding that C4 structural variants—requiring specialized imputation methods beyond standard GWAS analysis pipelines—are associated with schizophrenia,<sup>40</sup> and (3) the *SYNGAP1* gene, in which de novo mutations have already been implicated in schizophrenia<sup>41</sup> and other

neurodevelopmental disorders<sup>42,43</sup> ([supplementary figure 1](#)). Although we did not impute C4 structural variants in the present study, Sekar et al have previously reported that there is no remaining association in the class II region after adjusting for C4 variation in the PGC schizophrenia GWAS.<sup>40</sup> Thus, despite previous interpretations of the xMHC association in schizophrenia representing an autoimmune cause of disease,<sup>22,24,25</sup> we found no evidence for involvement of the HLA genes typically driving autoimmune susceptibility. We cannot disprove that genetic variation in the MHC may influence schizophrenia susceptibility via additional independent variants that did not reach significance in the present analysis, or underlying causal variants that were not captured in the current GWAS. Nevertheless, our findings suggest that our focus on immune genes outside of the xMHC was unlikely to have excluded from investigation common immune variants captured in the current GWAS that have a major role in schizophrenia.

### *Evaluating Collective Association of Immune Genes in Schizophrenia*

To determine whether current genetic data support an immune cause of schizophrenia, we first evaluated the summed association signal from genes encoding immune components using individual-level SNP data from the largest GWAS currently available<sup>2</sup> (25 629 cases and 30 976 controls of European ancestry). We observed evidence of inflation of the summed association test statistics for immune loci in schizophrenia ( $\lambda_{\text{immune}} = 1.48$ , empirical  $P < .01$ , [figure 1](#)), suggesting potential involvement of immune pathways in disease etiology. Given the substantial polygenic contribution to schizophrenia, some degree of inflation is expected even among a randomly selected set of SNPs.<sup>2</sup> To determine whether the collective association of immune SNPs exceeded that expected given the polygenic architecture of schizophrenia, we repeated the permutation analysis on a set of 973 randomly selected autosomal genes representing approximately the same proportion of SNPs as our immune gene set. We observed greater inflation of the summed association test statistic for this null gene set ( $\lambda_{\text{null}} = 1.54$ , empirical  $P < .01$ , [figure 1](#)), suggesting the collective association observed for immune SNPs was driven by the polygenicity of schizophrenia rather than specific involvement of immune loci in the disease.

### *Benchmarking Contribution of Immune Genes to Schizophrenia*

To benchmark genetically mediated immune pathway involvement, we quantified enrichment of heritability among immune SNPs compared to SNPs in the rest of the genome in schizophrenia and 5 diseases of known immune origin (Crohn's disease,<sup>28</sup> multiple sclerosis,<sup>29</sup> psoriasis,<sup>30</sup> rheumatoid arthritis,<sup>31</sup> and ulcerative colitis<sup>32</sup>). We




Fig. 1. 209 239 SNPs representing 973 randomly selected genes” to “290 239 SNPs representing 973 randomly selected genes.

estimated enrichment of immune SNPs using the recently developed stratified LD Score regression approach,<sup>36</sup> which uses multiple linear regression of  $\chi^2$  test statistics against LD Score with respect to functional categories to estimate category-specific enrichment of SNP-based heritability ( $h^2_{\text{SNP}}$ ). As expected based on previous literature and known biology, immune genes were consistently enriched 2- to 8-fold for  $h^2_{\text{SNP}}$  across all 5 autoimmune diseases ( $P < 5 \times 10^{-3}$ , figure 2 and table 2). In contrast to our findings in autoimmune diseases, immune genes were not enriched for heritability in schizophrenia ( $P = .94$ , figure 2 and table 2). As a separate approach we applied stratified false discovery rate (sFDR) control<sup>44</sup> to obtain enrichment estimates for immune genes, and again observed immune enrichment across the 5 autoimmune diseases but not schizophrenia (supplementary figure 2 and supplementary methods). Taken together, these results suggest that immune genes as a group may not be major drivers of schizophrenia risk.

It is possible that we were unable to detect true immune enrichment in schizophrenia due to its unique genetic and clinical architecture (highly polygenic and clinically heterogeneous) relative to the autoimmune diseases analyzed. As a positive control, we applied stratified LD Score regression to quantify enrichment of a set of brain genes previously reported to be enriched for schizophrenia heritability.<sup>45</sup> As expected, we observed significant enrichment of brain genes in schizophrenia ( $P = 1.14 \times 10^{-14}$ , figure 2 and table 2), indicating that we are able to detect true pathway enrichment in schizophrenia despite the high degree of polygenicity and clinical heterogeneity.

#### Identification of Immune Candidates Individually Associated With Schizophrenia

Although we found no overall enrichment of immune loci in schizophrenia, we hypothesized that individual immune genes may be implicated in the disease. Of the




Fig. 2. Estimated enrichment for immune (red) and brain (blue) genes in schizophrenia and 5 autoimmune diseases. The y-axis represents estimated enrichment for each gene set, defined as the proportion of heritability explained divided by the proportion of SNPs for that gene set. Values >1 (dotted line) indicate enrichment of heritability. Error bars represent enrichment estimates  $\pm$  standard error. \*\*\* $P < 1 \times 10^{-5}$ , \*\* $P < 1 \times 10^{-3}$ , \* $P < .01$  in a test of whether the estimated enrichment was equal to one. CRO, Crohn's disease; MS, multiple sclerosis; PSO, psoriasis; RA, rheumatoid arthritis; SCZ, schizophrenia; UC, ulcerative colitis.

108 previously reported loci associated with schizophrenia,<sup>2</sup> we identified 6 independent regions on chromosomes 2, 5, 8, 11, and 16 where the index SNP was an immune SNP (table 3, supplementary figure 3). To the best of our knowledge, none of these loci, which represented the *DPP4*, *HSPD1*, *EGRI*, *CLU*, *ESAM*, and *NFATC3* genes, have been previously associated with an autoimmune disease. All 6 of the immune genes associated with schizophrenia are expressed in human brain tissue<sup>46</sup> (supplementary figure 4). Interestingly, their protein products have roles in immune cell activation and adhesion, as well as established roles in the brain such as regulating myelination (*HSPD1*),<sup>47</sup> synaptic plasticity

**Table 2.** Enrichment and Per-SNP Heritability Estimates for Immune and Brain Gene Sets

| Disease                     | h <sup>2</sup> enrichment | SE          | P  | per-SNP h <sup>2</sup> ( $\tau_c$ )     | SE                                      | P                                       |
|-----------------------------|---------------------------|-------------|--|---|---|---|
| Immune gene set             |                           |             |  |   |   |   |
| Schizophrenia               | 1.01                      | 0.15        | .94                                      | $-7.01 \times 10^{-9}$                  | $1.11 \times 10^{-8}$                   | .53                                     |
| <b>Crohn's disease</b>      | <b>4.54</b>               | <b>0.66</b> | <b><math>6.80 \times 10^{-8}</math></b>  | <b><math>2.04 \times 10^{-7}</math></b> | <b><math>6.28 \times 10^{-8}</math></b> | <b><math>1.16 \times 10^{-3}</math></b> |
| <b>Multiple sclerosis</b>   | <b>8.56</b>               | <b>1.60</b> | <b><math>2.16 \times 10^{-6}</math></b>  | <b><math>1.49 \times 10^{-7}</math></b> | <b><math>2.84 \times 10^{-8}</math></b> | <b><math>1.55 \times 10^{-7}</math></b> |
| <b>Psoriasis</b>            | <b>7.08</b>               | <b>1.97</b> | <b><math>2.00 \times 10^{-3}</math></b>  | <b><math>2.26 \times 10^{-7}</math></b> | <b><math>7.17 \times 10^{-8}</math></b> | <b><math>1.62 \times 10^{-3}</math></b> |
| <b>Rheumatoid arthritis</b> | <b>5.18</b>               | <b>0.87</b> | <b><math>1.41 \times 10^{-6}</math></b>  | <b><math>1.01 \times 10^{-7}</math></b> | <b><math>2.70 \times 10^{-8}</math></b> | <b><math>1.83 \times 10^{-4}</math></b> |
| <b>Ulcerative colitis</b>   | <b>6.38</b>               | <b>0.93</b> | <b><math>7.36 \times 10^{-9}</math></b>  | <b><math>1.87 \times 10^{-7}</math></b> | <b><math>3.68 \times 10^{-8}</math></b> | <b><math>3.74 \times 10^{-7}</math></b> |
| Brain gene set              |                           |             |  |   |   |   |
| <b>Schizophrenia</b>        | <b>1.76</b>               | <b>0.10</b> | <b><math>1.14 \times 10^{-14}</math></b> | <b><math>4.04 \times 10^{-8}</math></b> | <b><math>9.24 \times 10^{-9}</math></b> | <b><math>1.23 \times 10^{-5}</math></b> |
| Crohn's disease             | 0.69                      | 0.15        | .04                                      | $-1.54 \times 10^{-8}$                  | $2.20 \times 10^{-8}$                   | .48                                     |
| Multiple sclerosis          | 0.14                      | 0.31        | $4.84 \times 10^{-3}$                    | $-1.27 \times 10^{-8}$                  | $1.11 \times 10^{-8}$                   | .25                                     |
| Psoriasis                   | 0.42                      | 0.53        | .27                                      | $-6.30 \times 10^{-9}$                  | $3.29 \times 10^{-8}$                   | .85                                     |
| Rheumatoid arthritis        | 0.85                      | 0.29        | .61                                      | $-4.61 \times 10^{-10}$                 | $1.21 \times 10^{-8}$                   | .97                                     |
| Ulcerative colitis          | 0.62                      | 0.24        | .11                                      | $-2.49 \times 10^{-9}$                  | $1.32 \times 10^{-8}$                   | .85                                     |

Note: Bold font indicates those SNP sets that are enriched based on both enrichment estimates and per-SNP h<sup>2</sup> estimates ( $\tau_c$ ).  $\tau_c$  estimates are obtained using a multivariate model that includes all other functional categories whereas the enrichment estimates only consider the functional category of interest. Therefore, when the enrichment estimate is significant without a significant  $\tau_c$  estimate, this suggests the result may be driven by correlation with other functional categories. SNP, single nucleotide polymorphism.

**Table 3.** Genome-Wide Significant Immune Genes in Schizophrenia

| SNP        | Chr | Position  | OR (95% CI)      | P                      | Gene          | Location <sup>a</sup> |
|------------|-----|-----------|------------------|------------------------|---------------|-----------------------|
| rs2909457  | 2   | 162845855 | 0.94 (0.92–0.96) | $4.38 \times 10^{-8}$  | <i>DPP4</i>   | +2.9 kb               |
| rs6434928  | 2   | 198304577 | 0.93 (0.91–0.95) | $1.48 \times 10^{-11}$ | <i>HSPD1</i>  | +46.7 kb              |
| rs3849046  | 5   | 137851192 | 1.06 (1.04–1.08) | $4.83 \times 10^{-9}$  | <i>EGR1</i>   | Intronic              |
| rs73229090 | 8   | 27442127  | 0.91 (0.88–0.94) | $1.95 \times 10^{-8}$  | <i>CLU</i>    | +12.3 kb              |
| rs55661361 | 11  | 124613957 | 0.92 (0.90–0.94) | $3.68 \times 10^{-12}$ | <i>ESAM</i>   | +9.1 kb               |
| rs8044995  | 16  | 68189340  | 1.08 (1.05–1.11) | $3.27 \times 10^{-8}$  | <i>NFATC3</i> | Intronic              |

<sup>a</sup>Location relative to immune gene of interest; +, downstream. SNP, single nucleotide polymorphism.

(*EGR1*),<sup>48</sup> blood–brain barrier permeability (*ESAM*),<sup>49</sup> and neuronal loss after brain injury (*NFATC3*,<sup>50</sup> *CLU*<sup>51</sup>).

**Discussion**

The hypothesis that schizophrenia may be an immunological disease is longstanding.<sup>3–5</sup> Using the largest collection of genetic data currently available, we evaluated the immune hypothesis of schizophrenia empirically. We have shown that common variation at immune genes presents a very different genetic architecture in schizophrenia as compared to diseases of known immune origin. First, the collective association of non-MHC immune genes in schizophrenia was not greater than expected given the polygenic architecture of the disease. Second, there was no enrichment of heritability among non-MHC immune genes in schizophrenia, in contrast to that observed in autoimmune diseases. While broad immune enrichment—or enrichment of specific immune pathways such as TGF- $\beta$  signaling, which has already been observed when pooling GWAS results across all major adult psychiatric disorders<sup>27</sup>—may be detected as GWAS sample

sizes increase further, our benchmarking establishes that the degree of enrichment in schizophrenia is substantially less than that seen in autoimmune diseases. Third, the immune loci that were individually associated with schizophrenia had important alternate roles in brain development and homeostasis, raising the possibility that proteins with dual immune-neural function are responsible for the link between schizophrenia and the immune system. For instance, *ESAM* regulates blood–brain barrier permeability,<sup>49</sup> and may influence susceptibility to schizophrenia by regulating exposure to the peripheral immune milieu. As samples available for genetic study increase in size and new genotyping approaches emerge, additional immune genes robustly associated with schizophrenia are likely to be discovered, and it will be critical to evaluate how these immune components may act in the brain.

Our methodological approach was subject to several important limitations. First, the immune gene list was broad, which may have diluted any enrichment in a more specific immune subset or pathway. Second, our annotation-based approach to defining the immune gene list did not capture remote regulatory regions for immune

genes. Third, the MHC region was excluded from all analyses subsequent to fine-mapping the MHC association. Due to extensive LD in the MHC region, current approaches for gene-enrichment analysis are not robust to inclusion of MHC variants and this is an important area of future methods development. Fourth, schizophrenia is an umbrella diagnosis that, like other complex disorders, likely captures many distinct molecular subtypes.<sup>52</sup> Thus, the broad phenotype classification used to define the patient cohort in the present study likely resulted in clinical heterogeneity within our sample. As immune disturbances may be causal in only a subset of schizophrenia patients, this clinical heterogeneity may have diluted association signals in the immune gene set. Fifth, our study was limited to common variants captured by current GWASs, which do not account completely for the estimated heritability of schizophrenia.<sup>53</sup> Finally, given evidence that exposure to inflammatory mediators in utero increases the risk of schizophrenia,<sup>54</sup> it may be maternal immune variation that contributes to the immune disturbances seen in patients with schizophrenia. Given these limitations, we cannot completely exclude a potential genetic etiology for the immune disturbances observed in schizophrenia.

Despite these limitations, to the best of our knowledge, this was the most comprehensive investigation of the hypothesis that immune genes contribute to schizophrenia. Based on current GWAS data, schizophrenia does not appear to be an autoimmune disease per se, although there may be modest contributions to genetic susceptibility from a specific subset of immune genes with additional roles outside of immunity (for example, neurodevelopmental). Our findings also raise the possibility that the immune disturbances observed in schizophrenia are of nongenetic etiology. Importantly, we cannot exclude the possible causal role of environmental risk factors that activate or “prime” the immune response (eg, infections, stress) in schizophrenia. Alternatively, the immune disturbances seen in schizophrenia may be a downstream factor in disease pathogenesis, fueling progression or modifying disease outcomes rather than initiating the disease. Finally, the immune changes observed in schizophrenia may simply be a byproduct of disease pathogenesis or patient lifestyle factors (ie, antipsychotic medication, smoking, and diet). Whether the immune abnormalities accompanying schizophrenia are causal, disease modifying, or epiphenomena is an important question to be addressed by longitudinal studies, particularly given burgeoning interest in potential immunotherapies.

### Web Resources

- Summary statistics:
  - Schizophrenia<sup>2</sup>: <http://www.med.unc.edu/pgc/files/resultfiles/scz2.snp.results.txt.gz%20%20>. Accessed May 4, 2016.
  - Crohn’s disease<sup>28</sup>: <ftp://ftp.sanger.ac.uk/pub4/ibdgenetics/cd-meta.txt.gz>. Accessed May 4, 2016.

- Rheumatoid arthritis<sup>31</sup>: [http://www.broadinstitute.org/ftp/pub/rheumatoid\\_arthritis/Stahl\\_et al\\_2010NG/](http://www.broadinstitute.org/ftp/pub/rheumatoid_arthritis/Stahl_et al_2010NG/). Accessed May 4, 2016.
- Ulcerative colitis<sup>32</sup>: <ftp://ftp.sanger.ac.uk/pub4/ibdgenetics/ucmeta-sumstats.txt.gz>. Accessed May 4, 2016.
- Stratified LD Score regression software<sup>36</sup>: [github.com/bulik/ldsc](https://github.com/bulik/ldsc). Accessed May 4, 2016.
- sFDR software<sup>44</sup>: <http://www.utstat.toronto.edu/sun/Software/SFDR>. Accessed May 4, 2016.

### Supplementary Material

Supplementary material is available at <http://schizophreniabulletin.oxfordjournals.org>.

### Funding

V.F.G. is supported by CIHR operating grant MOP115097. S.R. is supported by NIH grants U19-AI11224-01 and U01-HG007033-03. J.L.K. is supported by CIHR grant MOP 115097. J.K. is the Joanne Murphy Professor in Behavioural Science. J.G.P. is supported by Fulbright Canada, the Weston Foundation, and by Brain Canada through the Canada Brain Research Fund, a public-private partnership established by the Government of Canada. The funding sources did not influence the study design, data analysis, or writing of this manuscript.

### Acknowledgments

Computations were performed on the CAMH Specialized Computing Cluster (SCC), which is funded by The Canada Foundation for Innovation, Research Hospital Fund. We also thank SURFsara ([www.surfsara.nl](http://www.surfsara.nl)) for the support in using the Lisa Compute Cluster. We thank Richard Trembath, PhD (Queen Mary University of London) and Jonathan Barker, MD (King’s College London) for allowing us access to the imputed psoriasis GWAS data, and the IMSGC for providing us with access to the multiple sclerosis GWAS summary data. We also thank Lei Sun, PhD (University of Toronto) for providing the sFDR scripts, Lisa Strug, PhD (University of Toronto) for feedback on study design and the interpretation of the sFDR results, and Kamil Slowikowski, BSc (Harvard University) and Harm-Jan Westra, PhD (Harvard University) for assistance with writing and troubleshooting scripts for the permutation analysis. The authors have declared that there are no conflicts of interest in relation to the subject of this study.

### References

1. Sullivan PF, Kendler KS, Neale MC. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. *Arch Gen Psychiatry*. 2003;60:1187–1192.



2. Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. *Nature*. 2014;511:421–427.
3. Fessel WJ. Blood proteins in functional psychoses. A review of the literature and unifying hypothesis. *Arch Gen Psychiatry*. 1962;6:132–148.
4. Heath RG, Krupp IM. Schizophrenia as an immunologic disorder. I. Demonstration of antibody globulins by fluorescent antibody techniques. *Arch Gen Psychiatry*. 1967;16:1–9.
5. Mednick SA, Machon RA, Huttunen MO, Bonett D. Adult schizophrenia following prenatal exposure to an influenza epidemic. *Arch Gen Psychiatry*. 1988;45:189–192.
6. Beumer W, Gibney SM, Drexhage RC, et al. The immune theory of psychiatric diseases: a key role for activated microglia and circulating monocytes. *J Leukoc Biol*. 2012;92:959–975.
7. Huh GS, Boulanger LM, Du H, Riquelme PA, Brotz TM, Shatz CJ. Functional requirement for class I MHC in CNS development and plasticity. *Science*. 2000;290:2155–2159.
8. Stellwagen D, Malenka RC. Synaptic scaling mediated by glial TNF- $\alpha$ . *Nature*. 2006;440:1054–1059.
9. Schafer DP, Lehrman EK, Kautzman AG, et al. Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. *Neuron*. 2012;74:691–705.
10. Bialas AR, Stevens B. TGF- $\beta$  signaling regulates neuronal C1q expression and developmental synaptic refinement. *Nat Neurosci*. 2013;16:1773–1782.
11. Gallagher D, Norman AA, Woodard CL, et al. Transient maternal IL-6 mediates long-lasting changes in neural stem cell pools by deregulating an endogenous self-renewal pathway. *Cell Stem Cell*. 2013;13:564–576.
12. Smith SE, Li J, Garbett K, Mirnics K, Patterson PH. Maternal immune activation alters fetal brain development through interleukin-6. *J Neurosci*. 2007;27:10695–10702.
13. Short SJ, Lubach GR, Karasin AI, et al. Maternal influenza infection during pregnancy impacts postnatal brain development in the rhesus monkey. *Biol Psychiatry*. 2010;67:965–973.
14. Khandaker GM, Zimbron J, Dalman C, Lewis G, Jones PB. Childhood infection and adult schizophrenia: a meta-analysis of population-based studies. *Schizophr Res*. 2012;139:161–168.
15. Pearlman DM, Najjar S. Meta-analysis of the association between *N*-methyl-D-aspartate receptor antibodies and schizophrenia, schizoaffective disorder, bipolar disorder, and major depressive disorder. *Schizophr Res*. 2014;157:249–258.
16. Benros ME, Pedersen MG, Rasmussen H, Eaton WW, Nordentoft M, Mortensen PB. A nationwide study on the risk of autoimmune diseases in individuals with a personal or a family history of schizophrenia and related psychosis. *Am J Psychiatry*. 2014;171:218–226.
17. Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. *Biol Psychiatry*. 2011;70:663–671.
18. Fillman SG, Cloonan N, Catts VS, et al. Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia. *Mol Psychiatry*. 2013;18:206–214.
19. Miller AH, Raison CL. Are anti-inflammatory therapies viable treatments for psychiatric disorders?: where the rubber meets the road. *JAMA Psychiatry*. 2015;72:527–528.
20. Sommer IE, van Westrhenen R, Begemann MJ, de Witte LD, Leucht S, Kahn RS. Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update. *Schizophr Bull*. 2014;40:181–191.
21. Girgis RR. Tocilizumab as add-on treatment for residual positive, negative, and cognitive symptoms of schizophrenia. [ClinicalTrials.gov](http://ClinicalTrials.gov) [Internet]. Bethesda, MD: National Library of Medicine (US).
22. Horváth S, Mirnics K. Immune system disturbances in schizophrenia. *Biol Psychiatry*. 2014;75:316–323.
23. Haack M, Hinze-Selch D, Fenzel T, et al. Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis. *J Psychiatr Res*. 1999;33:407–418.
24. Stefansson H, Ophoff RA, Steinberg S, et al. Common variants conferring risk of schizophrenia. *Nature*. 2009;460:744–747.
25. Debnath M, Cannon DM, Venkatasubramanian G. Variation in the major histocompatibility complex [MHC] gene family in schizophrenia: associations and functional implications. *Prog Neuropsychopharmacol Biol Psychiatry*. 2013;42:49–62.
26. Jia P, Wang L, Meltzer HY, Zhao Z. Common variants conferring risk of schizophrenia: a pathway analysis of GWAS data. *Schizophr Res*. 2010;122:38–42.
27. Network and Pathway Analysis Subgroup of the Psychiatric Genomics Consortium. Psychiatric genome-wide association study analyses implicate neuronal, immune and histone pathways. *Nat Neurosci* 2015;18:199–209.
28. Franke A, McGovern DP, Barrett JC, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. *Nat Genet*. 2010;42:1118–1125.
29. Sawcer S, Hellenthal G, Pirinen M et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. *Nature* 2011;476:214–219.
30. Strange A, Capon F, Spencer CC et al. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. *Nat Genet* 2010;42:985–990.
31. Stahl EA, Raychaudhuri S, Remmers EF, et al. Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. *Nat Genet*. 2010;42:508–514.
32. Anderson CA, Boucher G, Lees CW, et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. *Nat Genet*. 2011;43:246–252.
33. Goyette P, Boucher G, Mallon D, et al. High-density mapping of the MHC identifies a shared role for HLA-DRB1\*01:03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis. *Nat Genet*. 2015;47:172–179.
34. Tsoi LC, Spain SL, Knight J, et al. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. *Nat Genet*. 2012;44:1341–1348.
35. Raychaudhuri S, Korn JM, McCarroll SA, et al. Accurately assessing the risk of schizophrenia conferred by rare copy-number variation affecting genes with brain function. *PLoS Genet*. 2010;6:e1001097.
36. Finucane H. Partitioning heritability by functional category using GWAS summary statistics. *bioRxiv*. 2015; doi:10.1101/014241.
37. Altshuler DM, Gibbs RA, Peltonen L et al. Integrating common and rare genetic variation in diverse human populations. *Nature* 2010;467:52–58.
38. Wang K, Li M, Hakonarson H. Analysing biological pathways in genome-wide association studies. *Nat Rev Genet*. 2010;11:843–854.
39. Mukherjee S, Ripke S, Andreassen O et al. Parsing genetic associations in the MHC in schizophrenia. Presented at



- 22nd World Congress of Psychiatric Genetics, Copenhagen, Denmark, 15 October 2014.
40. Sekar A, Bialas AR, de Rivera H, et al. Schizophrenia risk from complex variation of complement component 4. *Nature* 2016;530:177–183.
  41. Fromer M, Pocklington AJ, Kavanagh DH, et al. De novo mutations in schizophrenia implicate synaptic networks. *Nature*. 2014;506:179–184.
  42. O’Roak BJ, Stessman HA, Boyle EA, et al. Recurrent de novo mutations implicate novel genes underlying simplex autism risk. *Nat Commun*. 2014;5:5595.
  43. Hamdan FF, Gauthier J, Spiegelman D, et al. Mutations in SYNGAP1 in autosomal nonsyndromic mental retardation. *N Engl J Med*. 2009;360:599–605.
  44. Sun L, Craiu RV, Paterson AD, Bull SB. Stratified false discovery control for large-scale hypothesis testing with application to genome-wide association studies. *Genet Epidemiol*. 2006;30:519–530.
  45. Cross-Disorder Group of the Psychiatric Genomics Consortium. Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. *Nat Genet* 2013;45:984–994.
  46. Hawrylycz MJ, Lein ES, Guillozet-Bongaarts AL, et al. An anatomically comprehensive atlas of the adult human brain transcriptome. *Nature*. 2012;489:391–399.
  47. Magen D, Georgopoulos C, Bross P, et al. Mitochondrial hsp60 chaperonopathy causes an autosomal-recessive neurodegenerative disorder linked to brain hypomyelination and leukodystrophy. *Am J Hum Genet*. 2008;83:30–42.
  48. Jones MW, Errington ML, French PJ, et al. A requirement for the immediate early gene Zif268 in the expression of late LTP and long-term memories. *Nat Neurosci*. 2001;4:289–296.
  49. Nasdala I, Wolburg-Buchholz K, Wolburg H, et al. A transmembrane tight junction protein selectively expressed on endothelial cells and platelets. *J Biol Chem*. 2002;277:16294–16303.
  50. Gómez-Sintes R, Lucas JJ. NFAT/Fas signaling mediates the neuronal apoptosis and motor side effects of GSK-3 inhibition in a mouse model of lithium therapy. *J Clin Invest*. 2010;120:2432–2445.
  51. Han BH, DeMattos RB, Dugan LL, et al. Clusterin contributes to caspase-3-independent brain injury following neonatal hypoxia-ischemia. *Nat Med*. 2001;7:338–343.
  52. Stessman HA, Bernier R, Eichler EE. A genotype-first approach to defining the subtypes of a complex disease. *Cell*. 2014;156:872–877.
  53. Ripke S, O’Dushlaine C, Chambert K, et al. Genome-wide association analysis identifies 13 new risk loci for schizophrenia. *Nat Genet*. 2013;45:1150–1159.
  54. Canetta S, Sourander A, Surcel HM, et al. Elevated maternal C-reactive protein and increased risk of schizophrenia in a national birth cohort. *Am J Psychiatry*. 2014;171:960–968.